Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting

Masaaki Murakami, Kohichiro Iwasaki, Shozo Kusachi, Kazuyoshi Hina, Minoru Hirota, Satoshi Hirohata, Shigeshi Kamikawa, Mutsuko Sangawa, Keizo Yamamoto, Yasushi Shiratori

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Minor cardiac marker elevation after percutaneous coronary intervention has long-term prognostic significance. We examined whether nicorandil, a nicotinamide-nitrate ester, reduces the incidence of minor cardiac marker elevation after coronary stenting. Methods: Patients (n = 192) undergoing coronary stenting were randomly assigned to receive nicorandil (nicorandil group, n = 91) or vehicle (control group, n = 101). Nicorandil (2 μg/kg/min, intravenously) was administered immediately after the patients were transferred into the catheterization laboratory and continued for 6 h. We measured the serum concentrations of creatine kinase isoenzyme MB (CK-MB) before, immediately after, and 6, 12, and 24 h after the procedure, and those of cardiac troponin T (cTnT) 24 h after the procedure. Results: There was no significant difference in clinical background between the 2 groups. The nicorandil group showed a significantly lower incidence of CK-MB elevation (> 1 × upper limit of control range, 20 IU/l) than the control group (8.8% vs 21.8%, p <0.05). The levels of serum CK-MB in the nicorandil group were significantly lower than those in the control group (13.4 ± 5.7 vs 16.5 ± 9.7 IU/l, p <0.01). Similarly, the nicorandil group showed a significantly lower incidence of cTnT elevation [> 1 × (0.1 ng/ml) or > 2 × (0.2 ng/ml)] upper limit of control range than the control group (14.3% vs 26.7%, p <0.05, or 7.7% vs 17.8%, p <0.05). Serum cTnT levels were also significantly lower in the nicorandil group than in the control group (0.05 ± 0.10 vs 0.15 ± 0.36 ng/ml, p <0.05). Conclusions: The results demonstrated that nicorandil reduces minor cardiac marker elevation after coronary stenting.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalInternational Journal of Cardiology
Volume107
Issue number1
DOIs
Publication statusPublished - Feb 8 2006

Fingerprint

Nicorandil
Incidence
MB Form Creatine Kinase
Control Groups
Troponin T
Isoenzymes
Niacinamide
Percutaneous Coronary Intervention
Serum
Catheterization
Nitrates
Esters

Keywords

  • Coronary disease
  • Coronary intervention
  • Creatine kinase
  • Drugs
  • Myocardial injury
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting. / Murakami, Masaaki; Iwasaki, Kohichiro; Kusachi, Shozo; Hina, Kazuyoshi; Hirota, Minoru; Hirohata, Satoshi; Kamikawa, Shigeshi; Sangawa, Mutsuko; Yamamoto, Keizo; Shiratori, Yasushi.

In: International Journal of Cardiology, Vol. 107, No. 1, 08.02.2006, p. 48-53.

Research output: Contribution to journalArticle

Murakami, M, Iwasaki, K, Kusachi, S, Hina, K, Hirota, M, Hirohata, S, Kamikawa, S, Sangawa, M, Yamamoto, K & Shiratori, Y 2006, 'Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting', International Journal of Cardiology, vol. 107, no. 1, pp. 48-53. https://doi.org/10.1016/j.ijcard.2005.02.034
Murakami, Masaaki ; Iwasaki, Kohichiro ; Kusachi, Shozo ; Hina, Kazuyoshi ; Hirota, Minoru ; Hirohata, Satoshi ; Kamikawa, Shigeshi ; Sangawa, Mutsuko ; Yamamoto, Keizo ; Shiratori, Yasushi. / Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting. In: International Journal of Cardiology. 2006 ; Vol. 107, No. 1. pp. 48-53.
@article{8072bafaa6de40269ecde452dfedc012,
title = "Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting",
abstract = "Background: Minor cardiac marker elevation after percutaneous coronary intervention has long-term prognostic significance. We examined whether nicorandil, a nicotinamide-nitrate ester, reduces the incidence of minor cardiac marker elevation after coronary stenting. Methods: Patients (n = 192) undergoing coronary stenting were randomly assigned to receive nicorandil (nicorandil group, n = 91) or vehicle (control group, n = 101). Nicorandil (2 μg/kg/min, intravenously) was administered immediately after the patients were transferred into the catheterization laboratory and continued for 6 h. We measured the serum concentrations of creatine kinase isoenzyme MB (CK-MB) before, immediately after, and 6, 12, and 24 h after the procedure, and those of cardiac troponin T (cTnT) 24 h after the procedure. Results: There was no significant difference in clinical background between the 2 groups. The nicorandil group showed a significantly lower incidence of CK-MB elevation (> 1 × upper limit of control range, 20 IU/l) than the control group (8.8{\%} vs 21.8{\%}, p <0.05). The levels of serum CK-MB in the nicorandil group were significantly lower than those in the control group (13.4 ± 5.7 vs 16.5 ± 9.7 IU/l, p <0.01). Similarly, the nicorandil group showed a significantly lower incidence of cTnT elevation [> 1 × (0.1 ng/ml) or > 2 × (0.2 ng/ml)] upper limit of control range than the control group (14.3{\%} vs 26.7{\%}, p <0.05, or 7.7{\%} vs 17.8{\%}, p <0.05). Serum cTnT levels were also significantly lower in the nicorandil group than in the control group (0.05 ± 0.10 vs 0.15 ± 0.36 ng/ml, p <0.05). Conclusions: The results demonstrated that nicorandil reduces minor cardiac marker elevation after coronary stenting.",
keywords = "Coronary disease, Coronary intervention, Creatine kinase, Drugs, Myocardial injury, Stents",
author = "Masaaki Murakami and Kohichiro Iwasaki and Shozo Kusachi and Kazuyoshi Hina and Minoru Hirota and Satoshi Hirohata and Shigeshi Kamikawa and Mutsuko Sangawa and Keizo Yamamoto and Yasushi Shiratori",
year = "2006",
month = "2",
day = "8",
doi = "10.1016/j.ijcard.2005.02.034",
language = "English",
volume = "107",
pages = "48--53",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting

AU - Murakami, Masaaki

AU - Iwasaki, Kohichiro

AU - Kusachi, Shozo

AU - Hina, Kazuyoshi

AU - Hirota, Minoru

AU - Hirohata, Satoshi

AU - Kamikawa, Shigeshi

AU - Sangawa, Mutsuko

AU - Yamamoto, Keizo

AU - Shiratori, Yasushi

PY - 2006/2/8

Y1 - 2006/2/8

N2 - Background: Minor cardiac marker elevation after percutaneous coronary intervention has long-term prognostic significance. We examined whether nicorandil, a nicotinamide-nitrate ester, reduces the incidence of minor cardiac marker elevation after coronary stenting. Methods: Patients (n = 192) undergoing coronary stenting were randomly assigned to receive nicorandil (nicorandil group, n = 91) or vehicle (control group, n = 101). Nicorandil (2 μg/kg/min, intravenously) was administered immediately after the patients were transferred into the catheterization laboratory and continued for 6 h. We measured the serum concentrations of creatine kinase isoenzyme MB (CK-MB) before, immediately after, and 6, 12, and 24 h after the procedure, and those of cardiac troponin T (cTnT) 24 h after the procedure. Results: There was no significant difference in clinical background between the 2 groups. The nicorandil group showed a significantly lower incidence of CK-MB elevation (> 1 × upper limit of control range, 20 IU/l) than the control group (8.8% vs 21.8%, p <0.05). The levels of serum CK-MB in the nicorandil group were significantly lower than those in the control group (13.4 ± 5.7 vs 16.5 ± 9.7 IU/l, p <0.01). Similarly, the nicorandil group showed a significantly lower incidence of cTnT elevation [> 1 × (0.1 ng/ml) or > 2 × (0.2 ng/ml)] upper limit of control range than the control group (14.3% vs 26.7%, p <0.05, or 7.7% vs 17.8%, p <0.05). Serum cTnT levels were also significantly lower in the nicorandil group than in the control group (0.05 ± 0.10 vs 0.15 ± 0.36 ng/ml, p <0.05). Conclusions: The results demonstrated that nicorandil reduces minor cardiac marker elevation after coronary stenting.

AB - Background: Minor cardiac marker elevation after percutaneous coronary intervention has long-term prognostic significance. We examined whether nicorandil, a nicotinamide-nitrate ester, reduces the incidence of minor cardiac marker elevation after coronary stenting. Methods: Patients (n = 192) undergoing coronary stenting were randomly assigned to receive nicorandil (nicorandil group, n = 91) or vehicle (control group, n = 101). Nicorandil (2 μg/kg/min, intravenously) was administered immediately after the patients were transferred into the catheterization laboratory and continued for 6 h. We measured the serum concentrations of creatine kinase isoenzyme MB (CK-MB) before, immediately after, and 6, 12, and 24 h after the procedure, and those of cardiac troponin T (cTnT) 24 h after the procedure. Results: There was no significant difference in clinical background between the 2 groups. The nicorandil group showed a significantly lower incidence of CK-MB elevation (> 1 × upper limit of control range, 20 IU/l) than the control group (8.8% vs 21.8%, p <0.05). The levels of serum CK-MB in the nicorandil group were significantly lower than those in the control group (13.4 ± 5.7 vs 16.5 ± 9.7 IU/l, p <0.01). Similarly, the nicorandil group showed a significantly lower incidence of cTnT elevation [> 1 × (0.1 ng/ml) or > 2 × (0.2 ng/ml)] upper limit of control range than the control group (14.3% vs 26.7%, p <0.05, or 7.7% vs 17.8%, p <0.05). Serum cTnT levels were also significantly lower in the nicorandil group than in the control group (0.05 ± 0.10 vs 0.15 ± 0.36 ng/ml, p <0.05). Conclusions: The results demonstrated that nicorandil reduces minor cardiac marker elevation after coronary stenting.

KW - Coronary disease

KW - Coronary intervention

KW - Creatine kinase

KW - Drugs

KW - Myocardial injury

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=28944446896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28944446896&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2005.02.034

DO - 10.1016/j.ijcard.2005.02.034

M3 - Article

VL - 107

SP - 48

EP - 53

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -